MedTrace Logo

Development and Validation of Harbinger Health Test for Early Cancer Detection

NCT05435066 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8038

Last updated 2025-07-29

No results posted yet for this study

Summary

This is a prospective, multi-center, observational study with a collection of biospecimens and clinical data from approximately 10,000 participants from up to 125 clinical network sites and locations in the United States. The objective of this study is to collect blood samples, tissue samples, and associated clinical data from participants with a variety of solid tumor and hematologic cancers and non-cancer participants for testing and the development of a screening test for early cancer detection.

Conditions

Interventions

DIAGNOSTIC_TEST

Harbinger Health Test

This trial will be used to test the ability of the Harbinger Health test to detect cancer using blood-based biomarkers in a large cohort of patients with cancer and matched non-cancer controls. The non-cancer controls will be followed for up to 1 year

Sponsors & Collaborators

  • Harbinger Health

    lead INDUSTRY

Principal Investigators

  • Dax Kurbegov, MD · Sarah Cannon

  • Hutan Ashrafian, MD MBA PhD · Harbinger Health

  • Luke Pike, MD DPhil · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-21
Primary Completion
2025-06-11
Completion
2025-06-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05435066 on ClinicalTrials.gov